209 related articles for article (PubMed ID: 11862754)
1. [Biological and pathophysiological roles of endogenous methylarginines as inhibitors of nitric oxide synthase].
Masuda H; Azuma H
Nihon Yakurigaku Zasshi; 2002 Jan; 119(1):29-35. PubMed ID: 11862754
[TBL] [Abstract][Full Text] [Related]
2. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney.
Tojo A; Welch WJ; Bremer V; Kimoto M; Kimura K; Omata M; Ogawa T; Vallance P; Wilcox CS
Kidney Int; 1997 Dec; 52(6):1593-601. PubMed ID: 9407505
[TBL] [Abstract][Full Text] [Related]
3. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
Leiper J; Vallance P
Cardiovasc Res; 1999 Aug; 43(3):542-8. PubMed ID: 10690326
[TBL] [Abstract][Full Text] [Related]
4. Roles of accumulated endogenous nitric oxide synthase inhibitors and decreased nitric oxide synthase activity for impaired trigonal relaxation with ischemia.
Masuda H; Yano M; Sakai Y; Kihara K; Goto M; Azuma H
J Urol; 2003 Oct; 170(4 Pt 1):1415-20. PubMed ID: 14501780
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis.
MacAllister RJ; Fickling SA; Whitley GS; Vallance P
Br J Pharmacol; 1994 May; 112(1):43-8. PubMed ID: 7518309
[TBL] [Abstract][Full Text] [Related]
6. Localization and role of nitric oxide synthase and endogenous nitric oxide synthase inhibitors in the rabbit lower urinary tract.
Masuda H; Tsujii T; Okuno T; Kihara K; Goto M; Azuma H
J Urol; 2002 May; 167(5):2235-40. PubMed ID: 11956485
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.
Bełtowski J; Kedra A
Pharmacol Rep; 2006; 58(2):159-78. PubMed ID: 16702618
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
9. The methylarginines NMMA, ADMA, and SDMA are ubiquitous constituents of the main vegetables of human nutrition.
Servillo L; Giovane A; Cautela D; Castaldo D; Balestrieri ML
Nitric Oxide; 2013 Apr; 30():43-8. PubMed ID: 23438481
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide synthase inhibitors and hypertension in children and adolescents.
Goonasekera CD; Rees DD; Woolard P; Frend A; Shah V; Dillon MJ
J Hypertens; 1997 Aug; 15(8):901-9. PubMed ID: 9280214
[TBL] [Abstract][Full Text] [Related]
11. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
13. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T
Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
[TBL] [Abstract][Full Text] [Related]
14. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin.
Cardounel AJ; Xia Y; Zweier JL
J Biol Chem; 2005 Mar; 280(9):7540-9. PubMed ID: 15574418
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
Liu X; Xu X; Shang R; Chen Y
Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
[TBL] [Abstract][Full Text] [Related]
17. DdaR (PA1196) Regulates Expression of Dimethylarginine Dimethylaminohydrolase for the Metabolism of Methylarginines in Pseudomonas aeruginosa PAO1.
Lundgren BR; Bailey FJ; Moley G; Nomura CT
J Bacteriol; 2017 Apr; 199(8):. PubMed ID: 28167521
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
19. Developing a robust, fast and reliable measurement method for the analysis of methylarginine derivatives and related metabolites.
Eryavuz Onmaz D; Abusoglu S; Yaglioglu H; Abusoglu G; Unlu A
J Mass Spectrom Adv Clin Lab; 2021 Jan; 19():34-45. PubMed ID: 34820664
[TBL] [Abstract][Full Text] [Related]
20. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA.
Bulau P; Zakrzewicz D; Kitowska K; Leiper J; Gunther A; Grimminger F; Eickelberg O
Am J Physiol Lung Cell Mol Physiol; 2007 Jan; 292(1):L18-24. PubMed ID: 16891395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
